(Q35207282)

7 August 2017

1 reference

title

Early factors in successful anti-HIV treatment (English)

1 reference

7 August 2017

Peter J Piliero

1

1 reference

7 August 2017

publication date

1 January 2003

1 reference

Journal of the International Association of Providers of AIDS Care

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

1

1 reference

7 August 2017

page(s)

10-20

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Update on highly active antiretroviral therapy: progress and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Prevalence and predictive value of intermittent viremia with combination hiv therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Indinavir concentrations and antiviral effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Drugs as P-glycoprotein substrates, inhibitors, and inducers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Antiretroviral-drug resistance among patients recently infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The challenge of viral reservoirs in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Adverse metabolic consequences of HIV protease inhibitor therapy: the search for a central mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class∇

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

Nelfinavir: an update on its use in HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970300200102

10.1177/154510970300200102

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference